Chapter

Non-ischaemic cardiomyopathy

Dr Julian Ormerod and Michael Frenneaux

in Landmark Papers in Cardiovascular Medicine

Published on behalf of Oxford University Press

Published in print September 2012 | ISBN: 9780199594764
Published online November 2012 | e-ISBN: 9780191753480 | DOI: http://dx.doi.org/10.1093/med/9780199594764.003.0015

Series: Landmark Papers in

Non-ischaemic cardiomyopathy

Show Summary Details

Preview

From the glimpses provided in this chapter it will be clear that there have been huge advances in our understanding of the aetiological basis for the cardiomyopathies— particularly the molecular genetics—and of the pathophysiology of these disorders. However, it must be acknowledged that, thus far, these exciting data have not translated into specific therapies. Our recent paper demonstrating that the metabolic modulator perhexiline partially corrects cardiac energetic impairment in patients with hypertrophic cardiomyopathy, and that this translates into improved symptoms and exercise capacity, may be a forerunner of such therapeutic translation.

Chapter.  5688 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.